Quantcast

Point of Care Diagnostics, BCC Research

August 6, 2014

LONDON, Aug 6, 2014 /PRNewswire/ — Reportbuyer.com has added a new market research report:

Point of Care Diagnostics, BCC Research

http://www.reportbuyer.com/pharma_healthcare/diagnostics/point_care_diagnostics.html

STUDY GOALS AND OBJECTIVES

The goal of this study on the point-of-care (POC) industry is to describe and review business opportunities in the thriving near-patient testing market. This report provides a complete review and analysis of the current POC markets, and forecasts the market through 2018 in constant U.S. dollars. In addition, it provides an examination and description of select products, current and emerging technologies, and company profiles.The study also covers issues regarding regulation of POC testing, international developments and patents for POC testing technologies.

REASONS FOR DOING THE STUDY

Over the last few decades, there has been a strong trend toward POC testing due to an increasing demand for near-patient testing that provides rapid results. More tests are being performed at the hospital patient’s bedside, in physicians’ office laboratories, outpatient clinics, emergency rooms and intensive-care units. Critical-care instruments combining selected important chemistry, hematology and hemostasis parameters have entered the market for POC testing in emergency and operating rooms.The wider availability of POC testing has revolutionized the continuum of the patient-care process by providing laboratory results rapidly and efficiently at these locations. The trend toward greater POC testing is driven by the faster diagnostic benefits it provides.The heightened awareness of testing and identifying treatment targets via diagnostics tests has strengthened the role of POC tests in the health field. Using both diagnostics and treatments as a combination have been important advancements to optimal health treatment.Several reasons have emerged for this demand of POC testing, including staff shortages, older populations, long-term cost savings, faster diagnosis and care, and rural locations without conventional laboratory services. This study will address these areas and others.

CONTRIBUTION OF THE STUDY AND FOR WHOM

The intended audience includes all the stakeholders of the near-patient diagnostic testng market: diagnostic test manufacturing companies, medical supply vendors, hospitals, physician offices and groups, development companies and other involved participants. This includes mostly manufacturers, suppliers, technology providers, and research and development (R&D) companies.With its broad scope and in-depth analyses, this study will prove to be a valuable resource to anyone involved with or interested in the development of diagnostics test to the POC segment of the health industry. This study will provide information on these areas:
Structure and current market size of the POC market as outlined with forecasts through 2018.
Impact of chronic diseases, growing and aging populations.
Current product suppliers and some of their technologies.
A look at the diagnostic testing industry and trends affecting the market.
Markets by each segment provide a global overview showing market data for the U.S., Europe Asia and the rest of the world.
Technology patent trends relating to testing processes.
Profiles for more than 20 companies in the industry with significant contributions and market shares.
Since the study provides business and technical information of a timely nature, it will prove valuable to a variety of readers, including industry executives, managers and planners, purchasers, industry analysts and investors. The projections, forecasts and trend analyses found in this report provide readers with the necessary data and information for careful decision-making and what products will best meet the needs of the POC segment.

SCOPE OF REPORT

This study will describe the market for POC diagnostics at the global level. It focuses on the accelerating growth in this important diagnostic market segment and the key industry players. Specifically, the report:
Describes the POC industry.
Estimates the current and future market size.
Provides breakdowns for U.S. markets.
Describes product segments and the continuous updating of POC products.
Analyzes market influences in the industry and predicts the changes that will shape the future POC market.
Discusses trends within the market and provides a future outlook.
Reviews business activities of market leaders.
Lists patents for POC technologies.

DEFINING POC

For the purpose of this study, POC testing includes those tests that are used outside the traditional laboratory. This can be a range of users, including patients, physicians, outpatient clinics, community health centers and pharmacies. Tests included in this report are those that do not require any specialized training to perform, are performed easily and with results that are produced in a minimal time frame. Some other terms often used to describe POC include:
Waived tests.
Rapid tests.
Near-patient testing.
Bedside testing.
Outpatient testing.

Chapter- 1: INTRODUCTION – Complimentary 4

STUDY GOALS AND OBJECTIVES
REASONS FOR DOING THE STUDY
CONTRIBUTION OF THE STUDY AND FOR WHOM
SCOPE OF REPORT
DEFINING POC
METHODOLOGY
ANALYST’S CREDENTIALS
RELATED BCC RESEARCH REPORTS
BCC RESEARCH ONLINE SERVICES
DISCLAIMER

Chapter- 2: SUMMARY 3

OVERVIEW
MAJOR FINDINGS

Chapter- 3: INDUSTRY OVERVIEW 37

WHAT IS POC TESTING?
INDUSTRY TERMS (1)
OVERVIEW OF THE POC MARKET
POC AS PART OF CLINICAL DIAGNOSTICS INDUSTRY STRUCTURE
POC TESTING SITES
POC PRODUCT SEGMENTS
COMMONLY PERFORMED POC TESTS
SIGNIFICANCE OF CLIA IN THE UNITED STATES
THE FDA’S ROLE IN POC TESTING
DRIVING FORCES OF THE POC MARKET
ATTENTION TO DRUGS OF ABUSE

Chapter- 4: THE GLOBAL POC MARKET 10

MARKET OVERVIEW
COMPETITOR MARKET SHARE
MARKET STRUCTURE
MARKET COMPONENTS

Chapter- 5: BLOOD CHEMISTRY AND ELECTROLYTE TESTING 10

SEGMENT OVERVIEW
BLOOD CHEMISTRY PARAMETERS
MARKET SIZE
MARKET PARTICIPANTS AND MARKET SHARES

Chapter- 6: CARDIAC MARKER TESTING 6

SEGMENT OVERVIEW
MARKET SIZE
MARKET PARTICIPANTS AND MARKET SHARES

Chapter- 7: CHOLESTEROL TESTING 4

SEGMENT OVERVIEW
MARKET SIZE
MARKET PARTICIPANTS AND MARKET SHARES

Chapter- 8: DRUG AND ALCOHOL ABUSE TESTING 22

SEGMENT OVERVIEW
MARKET SIZE
MARKET PARTICIPANTS AND MARKET SHARES

Chapter- 9: GLUCOSE TESTING 22

SEGMENT OVERVIEW
MARKET SIZE
MARKET PARTICIPANTS AND MARKET SHARES

Chapter- 10: INFECTIOUS DISEASE TESTING 16

SEGMENT OVERVIEW
MARKET SIZE
MARKET PARTICIPANTS AND MARKET SHARES

Chapter- 11: PREGNANCY AND FERTILITY TESTING 7

SEGMENT OVERVIEW
MARKET SIZE
MARKET PARTICIPANTS AND MARKET SHARES

Chapter- 12: HEMOGLOBIN/HEMOSTASIS TESTING 4

HEMATOLOGY AND HEMOSTASIS
HEMOSTASIS (COAGULATION)
MARKET SIZE
MARKET PARTICIPANTS AND MARKET SHARES

Chapter- 13: TUMOR MARKER TESTING 5

SEGMENT OVERVIEW
FECAL AND GASTRIC OCCULT BLOOD
BLADDER TUMOR ANTIGEN TEST
MARKET SIZE
MARKET PARTICIPANTS AND MARKET SHARES

Chapter- 14: URINE CHEMISTRY TESTING 9

SEGMENT OVERVIEW
MARKET SIZE
MARKET PARTICIPANTS AND MARKET SHARES

Chapter- 15: MISC. TESTING 3

SEGMENT OVERVIEW

Chapter- 16: TECHNOLOGY APPLICATIONS 14

INTRODUCTION
ELECTRONIC DATA MANAGEMENT INTEGRATION
BIOSENSORS
ELECTRODES
CONTINUOUS TESTING
RAPID HIV TESTS
RAPID CLINICAL DRUG TESTING
TEARLAB CORP’S OSMOLARITY SYSTEM
PATENT ANALYSIS

Chapter- 17: GLOBAL POC MARKET 10

TOTAL MARKET SIZE
U.S. MARKET SIZE
INTERNATIONAL MARKET SIZE
GLOBAL MARKET SHARES
PRESENCE OF MANUFACTURERS IN THE WORLDWIDE MARKET

Chapter- 18: PROFILES OF MAJOR MARKET PARTICIPANTS 30

OVERVIEW OF MARKET PARTICIPANTS
COMPANY PROFILES

Chapter- 19: APPENDIX 8 $356

KEY SOURCES OF INFORMATION

List of Tables

Summary Table : GLOBAL FORECAST FOR THE POC MARKET, THROUGH 2018
Table 1 : SELECTED KEY STATISTICS FOR POC TESTING SITES
Table 2 : ESTIMATED NUMBER OF HOSPITALS/INPATIENT ACUTE CARE CENTERS AND BEDS AVAILABLE BY SELECTED COUNTRY, 2013
Table 3 : NURSING HOMES RESIDENTS BY SELECTED U.S. STATES, 2011
Table 4 : HOSPICE FACTS, 2011 VS. 2012
Table 5 : SELECTED POC TESTS-CLIA WAIVED
Table 6 : PERTINENT PARAMETERS OF GMP REGULATIONS AFFECTING IN VITRO DIAGNOSTICS
Table 7 : HEALTH EXPENDITURES AS PERCENTAGE OF GDP BY SELECT COUNTRY. 1980-2015
Table 8 : HEALTH EXPENDITURES AS PERCENTAGE OF GDP BY COUNTRY: TOP 20 SPENDERS, 2011
Table 9 : HOSPITAL USAGE STATISTICS, 2003 COMPARED TO 2011
Table 10 : WORLD HEALTH ORGANIZATION RANKING OF HEALTHCARE SYSTEMS, TOP 50, 2000
Table 11 : STATISTICS OF SELECTED DISEASES IN THE GLOBAL POPULATION, 2012-2013 ESTIMATES
Table 12 : BIRTH RATES AND BIRTHS BY COUNTRY, 2013 ESTIMATES
Table 13 : ESTIMATED GLOBAL POPULATION AND ANNUAL GROWTH BY SELECTED AGE GROUP AND SELECTED YEARS, THROUGH 2030
Table 14 : GLOBAL POPULATION BY SELECTED COUNTRY, THROUGH 2015
Table 15 : GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980 AND 2010
Table 16 : U.S. POPULATION ESTIMATES AND PROJECTIONS BY AGE GROUP, 1900-2050
Table 17 : ESTIMATES OF EXPECTED U.S. LIFE EXPECTANCY AT BIRTH WITH PROJECTIONS BY SEX, 1990-2020

Table 18 : GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980 AND 2013
Table 19 : GLOBAL FORECAST FOR THE POC MARKET BY TEST TYPE, THROUGH 2018
Table 20 : MARKET SHARE OF MAJOR POC MARKET PARTICIPANTS, 2013
Table 21 : FORECAST OF THE GLOBAL POC BLOOD GAS/ELECTROLYTE TESTING MARKET, THROUGH 2018
Table 22 : RELATIVE MARKET SHARE OF POC BLOOD CHEMISTRY ANALYZER MANUFACTURERS, 2013
Table 23 : ABAXIS PICCOLO ANALYZER TEST AVAILABILITY
Table 24 : NOVA BIOCHEMICAL POC STAT PROFILE PHOX SERIES BY AVAILABLE TESTS
Table 25 : FORECAST OF THE GLOBAL POC CARDIAC MARKER TESTING MARKET, THROUGH 2018
Table 26 : RELATIVE MARKET SHARE OF POC CARDIAC MARKER MANUFACTURERS, 2013
Table 27 : RECENT (2010-2013) CLIA-WAIVED APPROVED CARDIAC MARKER TESTS
Table 28 : FORECAST OF THE GLOBAL CHOLESTEROL POC RAPID TEST MARKET, THROUGH 2018
Table 29 : RELATIVE MARKET SHARE OF CHOLESTEROL POC RAPID TEST MANUFACTURERS, 2013
Table 30 : RECENT (2010-2013) CLIA-WAIVED APPROVED CHOLESTEROL TESTS
Table 31 : FORECAST OF THE GLOBAL DRUG AND ALCOHOL POC RAPID TEST MARKET, THROUGH 2018
Table 32 : RELATIVE MARKET SHARE OF DRUG AND ALCOHOL POC RAPID TEST MANUFACTURERS, 2013
Table 33 : RECENT (2010-2013) CLIA-WAIVED APPROVED POC DRUG AND ALCOHOL SCREENING TESTS
Table 34 : FORECAST OF THE GLOBAL POC GLUCOSE METER MARKET, THROUGH 2018
Table 35 : RELATIVE MARKET SHARE FOR GLUCOSE METERS AND SUPPLIES MANUFACTURERS, 2013
Table 36 : RECENT (2010-2013) CLIA-WAIVED APPROVED BLOOD GLUCOSE METERS
Table 37 : SELECTED LISTING OF RETAILERS SELLING HOME DIAGNOSTIC’S METERS
Table 38 : SELECT LISTING OF BLOOD GLUCOSE MONITORS CAPABLE OF INTERACTING WITH COMPUTER SOFTWARE
Table 39 : FORECAST OF THE GLOBAL INFECTIOUS DISEASE POC RAPID TEST MARKET, THROUGH 2018
Table 40 : ESTIMATED MARKET SHARE FOR THE GLOBAL POC INFECTIOUS DISEASE MARKET BY TEST TYPE, 2013

Table 41 : RELATIVE MARKET SHARE OF INFECTIOUS DISEASE POC RAPID TEST MANUFACTURERS, 2013
Table 42 : RECENT (2010-2013) CLIA-WAIVED APPROVED STREP A TESTS
Table 43 : RECENT (2010-2013) CLIA-WAIVED APPROVED INFLUENZA TESTS
Table 44 : RECENT (2010-2013) CLIA-WAIVED APPROVED CHLAMYDIA/TRICHOMONAS TESTS
Table 45 : RECENT (2010-2013) CLIA-WAIVED APPROVED RSV TESTS
Table 46 : RECENT (2010-2013) CLIA-WAIVED APPROVED HIV TESTS
Table 47 : RECENT (2010-2013) CLIA-WAIVED APPROVED INFECTIOUS MONONUCLEOSIS TESTS
Table 48 : RECENT (2010-2013) CLIA-WAIVED APPROVED H. PYLORI TESTS
Table 49 : RECENT (2010-2013) CLIA-WAIVED APPROVED HCV TESTS
Table 50 : RECENT (2010-2013) CLIA-WAIVED APPROVED ADENOVIRUS TESTS
Table 51 : FORECAST OF THE GLOBAL PREGNANCY/FERTILITY POC RAPID TEST MARKET, THROUGH 2018
Table 52 : MARKET SHARE FOR THE GLOBAL POC PREGNANCY/FERTILITY MARKET BY TEST TYPE, 2013
Table 53 : RELATIVE MARKET SHARE OF PREGNANCY/FERTILITY POC RAPID TEST MANUFACTURERS, 2013
Table 54 : RECENT (2010-2013) CLIA-WAIVED APPROVED PREGNANCY TESTS
Table 55 : FORECAST OF THE GLOBAL HEMOGLOBIN/HEMOSTASIS POC RAPID TEST MARKET, THROUGH 2018
Table 56 : RELATIVE MARKET SHARE OF HEMOGLOBIN/HEMOSTASIS POC RAPID TEST MANUFACTURERS, 2013
Table 57 : RECENT (2010-2013) CLIA-WAIVED APPROVED HEMATOLOGY TESTS
Table 58 : FORECAST OF THE GLOBAL TUMOR MARKER POC RAPID TEST MARKET, THROUGH 2018
Table 59 : RELATIVE MARKET SHARE OF TUMOR MARKER POC RAPID TEST MANUFACTURERS, 2013
Table 60 : RECENT (2010-2013) CLIA-WAIVED APPROVED FECAL OCCULT BLOOD TESTS
Table 61 : RECENT (2010-2013) CLIA-WAIVED APPROVED BLADDER TESTS
Table 62 : FORECAST OF THE GLOBAL POC URINE CHEMISTRY ANALYZER MARKET, THROUGH 2018
Table 63 : RELATIVE MARKET SHARE OF POC URINE CHEMISTRY ANALYZER MANUFACTURERS, 2013

Table 64 : RECENT (2010-2013) CLIA-WAIVED APPROVED URINE CHEMISTRY TESTS AND ANALYZERS
Table 65 : RECENT (2010-2013) CLIA-WAIVED APPROVED VAGINAL PH TESTS
Table 66 : RECENT (2010-2013) CLIA-WAIVED APPROVED TSH TESTS
Table 67 : RECENT (2010-2013) CLIA-WAIVED APPROVED MALE REPRODUCTIVE TESTS
Table 68 : RECENT (2010-2013) CLIA-WAIVED APPROVED MENOPAUSE TESTS
Table 69 : RECENT (2010-2013) CLIA-WAIVED APPROVED DRY EYE TESTS
Table 70 : U.S. PATENTS BY POC CATEGORY, JANUARY 2009 TO JANUARY 2014
Table 71 : U.S. PATENTS BY SUBJECT AREA, JANUARY 2009 TO JANUARY 2014
Table 72 : PATENT ASSIGNEES BY COUNTRY, JANUARY 2013 TO JANUARY 2014
Table 73 : GLOBAL FORECAST FOR THE POC MARKET, THROUGH 2018
Table 74 : U.S. FORECAST FOR THE POC MARKET, THROUGH 2018
Table 75 : INTERNATIONAL FORECAST FOR THE POC MARKET, THROUGH 2018
Table 76 : POC GLOBAL MARKET SHARE BY REGION, 2013
Table 77 : MARKET SHARE OF MAJOR POC MARKET PARTICIPANTS, 2013
Table 78 : ABAXIS’ COMPANY REVENUES, 2006-2013*
Table 79 : ABBOTT’S COMPANY REVENUES, 2006-2013
Table 80 : ALERE’S COMPANY REVENUES, 2006-2013
Table 81 : BECTON DICKINSON’S COMPANY REVENUES, 2006-2013*
Table 82 : CHEMBIO’S COMPANY SALES, 2006-2013
Table 83 : CHURCH & DWIGHT’S COMPANY REVENUES, 2006-2013
Table 84 : DANAHER’S COMPANY REVENUES, 2006-2013
Table 85 : HEMOCUE ESTIMATED REVENUES, 2010-2013
Table 86 : JOHNSON & JOHNSON’S COMPANY REVENUES, 2006-2013
Table 87 : NIPRO CORP.’S COMPANY REVENUES, 2006-2013*
Table 88 : ORASURE’S COMPANY REVENUES, 2006-2013
Table 89 : QUIDEL’S COMPANY REVENUES, 2006-2013
Table 90 : ROCHE GROUP’S REVENUES, 2006-2013
Table 91 : SEKISUI CHEMICAL CO.’S REVENUES, 2006-2013*
Table 92 : SIEMENS’ COMPANY REVENUES, 2006-2013*
Table 93 : TRINITY’S COMPANY REVENUES, 2006-2013
List of Figures

Summary Figure : FORECAST OF THE GLOBAL POC MARKET, 2009-2018
Figure 1 : ESTIMATED NUMBER OF INPATIENT CARE FACILITIES AND AVAILABLE BEDS BY SELECTED COUNTRY, 2013
Figure 2 : HEALTH EXPENDITURES AS PERCENTAGE OF GDP BY SELECT COUNTRY, 1980-2015
Figure 3 : HEALTH EXPENDITURES AS PERCENT OF GDP BY COUNTRY: TOP 20 SPENDERS, 2011
Figure 4 : HOSPITAL USAGE STATISTICS, 2003 AND 2011
Figure 5 : BIRTH RATES AND BIRTHS BY COUNTRY, 2013 ESTIMATES
Figure 6 : ESTIMATED GLOBAL POPULATION BY SELECTED AGE GROUP AND SELECTED YEARS, 2000-2030
Figure 7 : GLOBAL POPULATION BY SELECTED COUNTRY, 2010 AND 2015
Figure 8 : GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980 AND 2010
Figure 9 : U.S. POPULATION ESTIMATES AND PROJECTIONS BY AGE GROUP, 1900 TO 2050
Figure 10 : ESTIMATES OF EXPECTED U.S. LIFE EXPECTANCY AT BIRTH WITH PROJECTIONS BY SEX, 1990-2020
Figure 11 : GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980 AND 2013
Figure 12 : GLOBAL FORECAST FOR THE POC MARKET BY TEST TYPE, 2009-2018
Figure 13 : DISTRIBUTION OF SALES FOR THE GLOBAL POC MARKET BY TEST TYPE, 2013
Figure 14 : MARKET SHARE MAJOR POC MARKET PARTICIPANTS, 2013
Figure 15 : DISTRIBUTION CHANNELS: POC DIAGNOSTIC DEVICES
Figure 16 : FORECAST OF THE GLOBAL POC BLOOD GAS/ELECTROLYTE TESTING MARKET, 2009-2018
Figure 17 : RELATIVE MARKET SHARE BLOOD GAS ANALYZER MANUFACTURERS, 2013
Figure 18 : FORECAST OF THE GLOBAL POC CARDIAC MARKER TESTING MARKET, 2009-2018
Figure 19 : RELATIVE MARKET SHARE OF POC CARDIAC MARKER MANUFACTURERS, 2013
Figure 20 : FORECAST OF THE GLOBAL CHOLESTEROL POC RAPID TEST MARKET, 2009-2018
Figure 21 : RELATIVE MARKET SHARE OF CHOLESTEROL POC RAPID TEST MANUFACTURERS, 2013

Figure 22 : FORECAST OF THE GLOBAL DRUG AND ALCOHOL POC RAPID TEST MARKET, 2009-2018
Figure 23 : RELATIVE MARKET SHARE OF DRUG AND ALCOHOL POC RAPID TEST MANUFACTURERS, 2013
Figure 24 : FORECAST OF THE GLOBAL POC GLUCOSE METER MARKET, 2009-2018
Figure 25 : RELATIVE MARKET SHARE FOR GLUCOSE METERS AND SUPPLIES MANUFACTURERS, 2013
Figure 26 : FORECAST OF THE GLOBAL INFECTIOUS DISEASE POC RAPID TEST MARKET, 2009-2018
Figure 27 : ESTIMATED MARKET SHARE FOR THE GLOBAL POC INFECTIOUS DISEASE MARKET BY TEST TYPE, 2013
Figure 28 : RELATIVE MARKET SHARE OF INFECTIOUS DISEASE POC RAPID TEST MANUFACTURERS, 2013
Figure 29 : FORECAST OF THE GLOBAL INFECTIOUS DISEASE POC RAPID TEST MARKET, 2009-2018
Figure 30 : MARKET SHARE FOR THE GLOBAL POC PREGNANCY/FERTILITY MARKET BY TEST TYPE, 2013
Figure 31 : RELATIVE MARKET SHARE OF PREGNANCY/FERTILITY POC RAPID TEST MANUFACTURERS, 2013
Figure 32 : FORECAST OF THE GLOBAL HEMOGLOBIN/HEMOSTASIS POC RAPID TEST MARKET, 2009-2018
Figure 33 : RELATIVE MARKET SHARE OF HEMOGLOBIN/HEMOSTASIS POC RAPID TEST MANUFACTURERS, 2013
Figure 34 : FORECAST OF THE GLOBAL TUMOR MARKER POC RAPID TEST MARKET, 2009-2018
Figure 35 : RELATIVE MARKET SHARE OF TUMOR MARKER POC RAPID TEST MANUFACTURERS, 2013
Figure 36 : FORECAST OF THE GLOBAL POC URINE CHEMISTRY ANALYZER MARKET, 2009-2018
Figure 37 : RELATIVE MARKET SHARE OF POC URINE CHEMISTRY ANALYZER MANUFACTURERS, 2013
Figure 38 : U.S. PATENTS BY POC CATEGORY, JANUARY 2009 TO JANUARY 2014
Figure 39 : U.S. PATENTS BY SUBJECT AREA, JANUARY 2009 TO JANUARY 2014
Figure 40 : PATENT ASSIGNEES BY COUNTRY, JANUARY 2013 TO JANUARY 2014
Figure 41 : GLOBAL FORECAST FOR THE POC MARKET, 2009-2018

Figure 42 : U.S. FORECAST FOR THE POC MARKET, 2009-2018
Figure 43 : INTERNATIONAL FORECAST FOR THE POC MARKET, 2009-2018
Figure 44 : POC GLOBAL MARKET SHARE BY REGION, 2013
Figure 45 : NORTH AMERICAN POC MARKET SHARE BY COUNTRY, 2013
Figure 46 : EUROPEAN POC MARKET SHARE BY COUNTRY, 2013
Figure 47 : ASIAN POC MARKET SHARE BY COUNTRY, 2013
Figure 48 : MARKET SHARE MAJOR POC MARKET PARTICIPANTS, 2013
Figure 49 : ABAXIS’ COMPANY REVENUES, 2006-2013*
Figure 50 : ABBOTTS’ COMPANY REVENUES, 2006-2013
Figure 51 : ALERE’S COMPANY REVENUES 2006-2013
Figure 52 : BECTON DICKINSON’S COMPANY REVENUES, 2006-2013*
Figure 53 : CHEMBIO’S COMPANY SALES, 2006-2013
Figure 54 : CHURCH & DWIGHT’S COMPANY REVENUES, 2006-2013
Figure 55 : DANAHER’S COMPANY REVENUES, 2006-2013
Figure 56 : HEMOCUE ESTIMATED REVENUES, 2010-2013
Figure 57 : JOHNSON & JOHNSON’S COMPANY REVENUES, 2006-2013
Figure 58 : NIPRO CORP.’S COMPANY REVENUES, 2006-2013*
Figure 59 : ORASURE’S COMPANY REVENUES, 2006-2013
Figure 60 : QUIDEL’S COMPANY REVENUES, 2006-2013
Figure 61 : ROCHE GROUP’S REVENUES, 2006-2013
Figure 62 : SEKISUI CHEMICAL CO.’S REVENUES, 2006-2013*
Figure 63 : SIEMENS’ COMPANY REVENUES, 2006-2013*
Figure 64 : TRINITY’S COMPANY REVENUES, 2006-2013

Read the full report:
Point of Care Diagnostics, BCC Research

http://www.reportbuyer.com/pharma_healthcare/diagnostics/point_care_diagnostics.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer


Source: PR Newswire



comments powered by Disqus